Trevi Therapeutics Inc

Company Profile

Trevi Therapeutics Inc had its IPO on 2019-05-07 under the ticker symbol TRVI.

The company operates in the Healthcare sector and Biotechnology industry. Trevi Therapeutics Inc has a staff strength of 30 employees.

Stock update

Shares of Trevi Therapeutics Inc opened at $2.27 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.14 - $2.27, and closed at $2.19.

This is a -3.32% slip from the previous day's closing price.

A total volume of 27,878 shares were traded at the close of the day’s session.

In the last one week, shares of Trevi Therapeutics Inc have slipped by -5%.

Trevi Therapeutics Inc's Key Ratios

Trevi Therapeutics Inc has a market cap of $146.86 million, indicating a price to book ratio of 1.2704 and a price to sales ratio of 0.

In the last 12-months Trevi Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-30930000. The EBITDA ratio measures Trevi Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Trevi Therapeutics Inc’s operating margin was 0% while its return on assets stood at -21.25% with a return of equity of -35.11%.

In Q2, Trevi Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Trevi Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.24 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Trevi Therapeutics Inc’s profitability.

Trevi Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.805. Its price to sales ratio in the trailing 12-months stood at 0.

Trevi Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$100.98 million

Total Liabilities

$4.71 million

Operating Cash Flow

$0

Capital Expenditure

$40000

Dividend Payout Ratio

0%

Trevi Therapeutics Inc ended 2024 with $100.98 million in total assets and $0 in total liabilities. Its intangible assets were valued at $100.98 million while shareholder equity stood at $95.07 million.

Trevi Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.71 million in other current liabilities, 63000.00 in common stock, $-223615000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $13.75 million and cash and short-term investments were $94.15 million. The company’s total short-term debt was $277,000 while long-term debt stood at $0.

Trevi Therapeutics Inc’s total current assets stands at $99.21 million while long-term investments were $0 and short-term investments were $80.40 million. Its net receivables were $0 compared to accounts payable of $1.35 million and inventory worth $0.

In 2024, Trevi Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $40000.

Comparatively, Trevi Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.19

52-Week High

$3.5

52-Week Low

$1.43

Analyst Target Price

$7.33

Trevi Therapeutics Inc stock is currently trading at $2.19 per share. It touched a 52-week high of $3.5 and a 52-week low of $3.5. Analysts tracking the stock have a 12-month average target price of $7.33.

Its 50-day moving average was $2.28 and 200-day moving average was $2.32 The short ratio stood at 13.75 indicating a short percent outstanding of 0%.

Around 369.2% of the company’s stock are held by insiders while 8398.6% are held by institutions.